Literature DB >> 23982684

Bile acid receptors as targets for drug development.

Frank G Schaap1, Michael Trauner2, Peter L M Jansen3.   

Abstract

The intracellular nuclear receptor farnesoid X receptor and the transmembrane G protein-coupled receptor TGR5 respond to bile acids by activating transcriptional networks and/or signalling cascades. These cascades affect the expression of a great number of target genes relevant for bile acid, cholesterol, lipid and carbohydrate metabolism, as well as genes involved in inflammation, fibrosis and carcinogenesis. Pregnane X receptor, vitamin D receptor and constitutive androstane receptor are additional nuclear receptors that respond to bile acids, albeit to a more restricted set of species of bile acids. Recognition of dedicated bile acid receptors prompted the development of semi-synthetic bile acid analogues and nonsteroidal compounds that target these receptors. These agents hold promise to become a new class of drugs for the treatment of chronic liver disease, hepatocellular cancer and extrahepatic inflammatory and metabolic diseases. This Review discusses the relevant bile acid receptors, the new drugs that target bile acid signalling and their possible applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23982684     DOI: 10.1038/nrgastro.2013.151

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  207 in total

Review 1.  Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs.

Authors:  Tiara R Ahmad; Rebecca A Haeusler
Journal:  Nat Rev Endocrinol       Date:  2019-10-15       Impact factor: 43.330

2.  The association between gut microbiota development and maturation of intestinal bile acid metabolism in the first 3 y of healthy Japanese infants.

Authors:  Masaru Tanaka; Masafumi Sanefuji; Seiichi Morokuma; Misako Yoden; Rie Momoda; Kenji Sonomoto; Masanobu Ogawa; Kiyoko Kato; Jiro Nakayama
Journal:  Gut Microbes       Date:  2019-09-24

Review 3.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

4.  Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.

Authors:  Shogo Takahashi; Yuhuan Luo; Suman Ranjit; Cen Xie; Andrew E Libby; David J Orlicky; Alexander Dvornikov; Xiaoxin X Wang; Komuraiah Myakala; Bryce A Jones; Kanchan Bhasin; Dong Wang; James L McManaman; Kristopher W Krausz; Enrico Gratton; Diana Ir; Charles E Robertson; Daniel N Frank; Frank J Gonzalez; Moshe Levi
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

5.  TGR5 in the Cholangiociliopathies.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

6.  Bile acid signaling and bariatric surgery.

Authors:  Jingyan Tian; Silvia Huang; Siming Sun; Lili Ding; Eryun Zhang; Wendong Huang
Journal:  Liver Res       Date:  2017-12

Review 7.  Bile acids are nutrient signaling hormones.

Authors:  Huiping Zhou; Phillip B Hylemon
Journal:  Steroids       Date:  2014-05-10       Impact factor: 2.668

8.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

Review 9.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

10.  Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice.

Authors:  Xiaoyan Zhang; Shizheng Huang; Min Gao; Jia Liu; Xiao Jia; Qifei Han; Senfeng Zheng; Yifei Miao; Shuo Li; Haoyu Weng; Xuan Xia; Shengnan Du; Wanfu Wu; Jan-Åke Gustafsson; Youfei Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.